Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells

NCT07041801 | Recruiting Phase 1

• 1 other identifier: BK-SLE-I/01
• Study Type: interventional
• Target: 58
• Locations: 1 country
• Sites: 1

Brief Summary

This study will investigate the safety and efficacy of allogeneic umbilical cord-derived stem cell therapy in treating patients with moderate to severe systemic lupus erythematosus.

Conditions

Systemic Lupus Erythematosus (SLE)

Outcome Measures

Primary Outcomes (1)

• Incidence of Treatment-Emergent Adverse Events

  Analysis for the primary endpoint will be descriptive in nature. safety and tolerability will be measured by the number of AEs and SAEs observed. Adverse event incidents will be summarized descriptively. The severity grade of each recorded AE, and their relationship to study treatment will be analyzed. The action taken and outcome will also be analyzed accordingly.

  day 1 to day 28

Secondary Outcomes (1)

• Efficacy Endpoint

  The 24th week after administration of the test drug.

Study Arms (5)

hUC-MSCs treatment (low dose)

EXPERIMENTAL

Conventional plus hUC-MSCs treatment (low dose)

Drug: hUC-MSCs treatment (low dose)

hUC-MSCs treatment （medium dose）

EXPERIMENTAL

conventional therapy plus hUC-MSCs treatment （medium dose）

Biological: hUC-MSCs treatment (medium dose)

hUC-MSCs treatment （high dose）

EXPERIMENTAL

conventional therapy plus hUC-MSCs treatment （high dose）

Biological: hUC-MSCs treatment (high dose)

hUC-MSCs treatment （Double dose）

EXPERIMENTAL

conventional therapy plus hUC-MSCs treatment（Double dose）

Biological: hUC-MSCs treatment （Double dose）

Placebo

PLACEBO COMPARATOR

conventional therapy plus Placebo

Drug: Placebo

Interventions

hUC-MSCs treatment (low dose) DRUG

patients will receive conventional therapy plus low dose hUC-MSCs treatment,The dosage is 1E6 cells/kg.

hUC-MSCs treatment (low dose)

hUC-MSCs treatment (medium dose) BIOLOGICAL

patients will receive conventional therapy plus medium dose hUC-MSCs treatment,The dosage is 3E6 cells/kg.

Also known as: MSC-medium

hUC-MSCs treatment （medium dose）

hUC-MSCs treatment (high dose) BIOLOGICAL

patients will receive conventional therapy plus high dose hUC-MSCs treatment,The dosage is 5E6 cells/kg.

Also known as: MSC-high

hUC-MSCs treatment （high dose）

Placebo DRUG

patients will receive conventional therapy plus Placebo

Placebo

hUC-MSCs treatment （Double dose） BIOLOGICAL

Double dosing is selected by the investigators and the sponsor based on the data from the single-dose part of the study. One superior dose is chosen for multiple dosing (tentatively set at 3E6 cells/kg, administered twice with an interval of 4 weeks; the actual dose, frequency and interval of multiple dosing can be adjusted according to the available data). During the trial, stable standard treatment is allowed.

hUC-MSCs treatment （Double dose）

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Fully understand the purpose, nature, methods of the trial and possible adverse reactions, voluntarily become a subject, and sign the informed consent form.
• Age 18-65 years old (inclusive of the boundary values, based on the time of signing the informed consent form), no gender restrictions;
• The subjects (male and female) must agree not to have a reproductive plan during the trial period and after the injection administration for at least 12 months, and voluntarily take effective contraceptive measures with their partners (see Appendix 1), and have no plans for sperm donation or egg donation;
• According to the diagnostic classification criteria of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) in 2019, diagnosed with systemic lupus erythematosus (SLE);
• Meet one of the following conditions: the antinuclear antibody (ANA) is positive at 1:80 during screening or the anti-dsDNA antibody is positive during screening or the anti-Sm antibody is positive during screening;

You may not qualify if:

• Those who are judged by the researchers to be likely to be allergic to the investigational drug or any component thereof;
• Those who have had central nervous system diseases within 8 weeks before administration (including but not limited to epilepsy, mental illness, interstitial encephalopathy syndrome, stroke, encephalitis, central nervous system vasculitis, etc.);
• Those who have undergone major organ transplantation (such as heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplantation;
• Those who have any major diseases/diseases or unstable clinical conditions (such as liver, kidney, hematological, endocrine, pulmonary, immune, mental, etc.) or active infections/infectious diseases with evidence, and according to the researchers' clinical judgment, if the subjects participate in the study, it will significantly increase the risks for the subjects;
• Those who currently have known or suspected malignant tumors;
• Those who have severe pulmonary arterial hypertension (\>70 mmHg, 1 mmHg = 0.133 kPa), or mild to moderate pulmonary arterial hypertension patients with severe cardiopulmonary insufficiency;
• Those who have antiphospholipid syndrome (APS), or have a history of catastrophic antiphospholipid syndrome (CAPS), or although not diagnosed as APS, but are evaluated by the researchers as having an increased risk of thrombosis;
• Those who have herpes zoster infection within 90 days before administration, or any infection that requires hospitalization treatment or intravenous or intramuscular injection of antibiotics within 60 days before administration;
• Those who have undergone major surgical operations within 28 days before administration, or those who are expected to undergo major surgical operations during the trial;
• Subjects who have positive serological tests for viral hepatitis during the screening period, positive human immunodeficiency virus antibody (HIV-Ab), positive hepatitis B surface antigen (HBsAg), positive hepatitis C antibody (HCV-Ab), or positive Treponema pallidum antibody (TP-Ab);
• Other situations that the researchers consider may affect the subjects' willingness to provide informed consent or follow the trial protocol, or situations where the subjects' participation in the trial may affect the trial results or their own safety.

Sponsors & Collaborators

• Shenzhen Beike Bio-Technology Co., Ltd.: lead

Study Sites (1)

Shenzhen Beike Bio-Technology Co. Ltd.

Shenzhen, Guangdong, 518000, China

RECRUITING

MeSH Terms

Conditions

Lupus Erythematosus, Systemic

Condition Hierarchy (Ancestors)

Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 27, 2025
• First Posted: June 27, 2025
• Study Start: June 28, 2025
• Primary Completion (Estimated): September 5, 2027
• Study Completion (Estimated): December 28, 2027
• Last Updated: June 27, 2025

Record last verified: 2025-06

Locations

CN (1)